CL2021003568A1 - Heteroaromatic Compounds as Vanin Inhibitors (Application Divisional No. 202101198) - Google Patents

Heteroaromatic Compounds as Vanin Inhibitors (Application Divisional No. 202101198)

Info

Publication number
CL2021003568A1
CL2021003568A1 CL2021003568A CL2021003568A CL2021003568A1 CL 2021003568 A1 CL2021003568 A1 CL 2021003568A1 CL 2021003568 A CL2021003568 A CL 2021003568A CL 2021003568 A CL2021003568 A CL 2021003568A CL 2021003568 A1 CL2021003568 A1 CL 2021003568A1
Authority
CL
Chile
Prior art keywords
heteroaromatic compounds
application divisional
vanin
compounds
inhibitors
Prior art date
Application number
CL2021003568A
Other languages
Spanish (es)
Inventor
Cédrickx Godbout
Martin Thomas Fleck
Hannes Fiepko Koolman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2021003568A1 publication Critical patent/CL2021003568A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Abstract

La presente invención abarca los compuestos de la Fórmula I I, que son adecuados para el tratamiento de enfermedades relacionadas con vanina, y los procesos para fabricar estos compuestos, las preparaciones farmacéuticas que contienen estos compuestos y sus métodos de uso.The present invention encompasses the compounds of the Formula I I, which are suitable for the treatment of vanin-related diseases, and the processes for manufacturing these compounds, the pharmaceutical preparations containing these compounds and their methods of use.

CL2021003568A 2018-12-03 2021-12-30 Heteroaromatic Compounds as Vanin Inhibitors (Application Divisional No. 202101198) CL2021003568A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18209721 2018-12-03

Publications (1)

Publication Number Publication Date
CL2021003568A1 true CL2021003568A1 (en) 2022-11-04

Family

ID=64572152

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001198A CL2021001198A1 (en) 2018-12-03 2021-05-06 Heteroaromatic compounds as vanine inhibitors
CL2021003568A CL2021003568A1 (en) 2018-12-03 2021-12-30 Heteroaromatic Compounds as Vanin Inhibitors (Application Divisional No. 202101198)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021001198A CL2021001198A1 (en) 2018-12-03 2021-05-06 Heteroaromatic compounds as vanine inhibitors

Country Status (23)

Country Link
US (3) US11078182B2 (en)
EP (1) EP3891139A1 (en)
JP (2) JP7130873B2 (en)
KR (1) KR20210100150A (en)
CN (2) CN113166104A (en)
AR (1) AR117229A1 (en)
AU (1) AU2019391279A1 (en)
BR (1) BR112021007915A2 (en)
CA (1) CA3116830A1 (en)
CL (2) CL2021001198A1 (en)
CO (1) CO2021007173A2 (en)
CR (1) CR20210294A (en)
DO (1) DOP2021000071A (en)
EA (1) EA202191476A1 (en)
EC (1) ECSP21040278A (en)
IL (1) IL283397A (en)
JO (2) JOP20210128A1 (en)
MA (1) MA54378A (en)
MX (1) MX2021006520A (en)
PE (1) PE20211769A1 (en)
PH (1) PH12021551280A1 (en)
SG (1) SG11202104437XA (en)
WO (1) WO2020114943A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3844161T3 (en) 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors.
JP7195436B2 (en) * 2018-12-03 2022-12-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heteroaromatic compounds as vanin inhibitors
AR117229A1 (en) * 2018-12-03 2021-07-21 Boehringer Ingelheim Int HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN116768909A (en) * 2022-03-18 2023-09-19 上海美悦生物科技发展有限公司 Salt form and crystal form of Vanin enzyme inhibitor, and preparation methods and applications thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
DE602004018811D1 (en) 2003-10-09 2009-02-12 Abbott Lab PYRROLIDINE HYDROGEN DERIVATIVES AS ANGIOGENESE INHIBITORS
US9585891B2 (en) 2012-09-25 2017-03-07 Merck Patent Gmbh Alpha hydroxy amides
EP3303303A1 (en) * 2015-05-29 2018-04-11 Pfizer Inc Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
AU2017296338A1 (en) 2016-07-14 2019-01-03 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
ES2927021T3 (en) 2017-06-12 2022-11-02 Boehringer Ingelheim Int Heteroaromatics as vanin inhibitors
DK3844161T3 (en) 2018-08-28 2022-12-12 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors.
JP7195436B2 (en) * 2018-12-03 2022-12-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Heteroaromatic compounds as vanin inhibitors
US20220041592A1 (en) * 2018-12-03 2022-02-10 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
AR117229A1 (en) * 2018-12-03 2021-07-21 Boehringer Ingelheim Int HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS

Also Published As

Publication number Publication date
PH12021551280A1 (en) 2021-12-06
JOP20210128A1 (en) 2023-01-30
US20200172508A1 (en) 2020-06-04
WO2020114943A1 (en) 2020-06-11
BR112021007915A2 (en) 2021-07-27
IL283397A (en) 2021-07-29
CR20210294A (en) 2021-08-13
CN113166104A (en) 2021-07-23
AU2019391279A1 (en) 2021-05-13
MX2021006520A (en) 2021-07-07
AR117229A1 (en) 2021-07-21
CN114478485A (en) 2022-05-13
EA202191476A1 (en) 2021-10-26
CA3116830A1 (en) 2020-06-11
SG11202104437XA (en) 2021-05-28
CO2021007173A2 (en) 2021-06-21
CN114478485B (en) 2024-04-05
MA54378A (en) 2022-03-09
US20230295112A1 (en) 2023-09-21
CL2021001198A1 (en) 2021-12-24
TW202039461A (en) 2020-11-01
US20220048885A1 (en) 2022-02-17
JOP20210127A1 (en) 2023-01-30
JP7130873B2 (en) 2022-09-05
JP2022509317A (en) 2022-01-20
EP3891139A1 (en) 2021-10-13
JP2022188014A (en) 2022-12-20
ECSP21040278A (en) 2021-07-30
KR20210100150A (en) 2021-08-13
DOP2021000071A (en) 2021-05-31
US11078182B2 (en) 2021-08-03
PE20211769A1 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
CO2021005987A2 (en) Fused ring compounds
CO2018005954A2 (en) Heteroaromatic compounds as btk inhibitors
CL2021003568A1 (en) Heteroaromatic Compounds as Vanin Inhibitors (Application Divisional No. 202101198)
CO2021003036A2 (en) Fused Ring Compounds
CL2019002777A1 (en) Compounds that inhibit the mcl-1 protein.
CO2019013823A2 (en) Heteroaromatic compounds as vanin inhibitors
ECSP21013743A (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
ECSP15008851A (en) HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
CL2021001395A1 (en) Compounds derived from cyclic pantheines; pharmaceutical composition comprising them; and its use to increase the concentrations of acetyl-coa, for the treatment of cancer, inflammatory disease, neurodegenerative disease, multiple sclerosis, among other diseases.
CL2017001073A1 (en) 2,4 diamino-quinolia substituted as new anticancer agents
DOP2018000238A (en) ZESTE HOMOLOGIST ENHANCER INHIBITORS 2
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
CL2019002583A1 (en) Dual inhibitors of magl and faah.
CL2020001107A1 (en) Novel pyrazolo-pyrrolo-pyrimidine derivatives as p2x3 inhibitors.
CL2022003703A1 (en) Antibiotic compounds, their manufacturing methods, pharmaceutical compositions containing them and uses
EA202191477A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
UY38133A (en) NEW INHIBITORS FROM CDK8 / 19
CL2021001944A1 (en) Amino acid derivatives for the treatment of inflammatory diseases